Research Of Repair Of Diabetic Erectile Dysfunction By Bone Marrow Mesenchymal Stem Cells

Objective:In our county and the world, the incidence of male erectiledysfunction has been high, and there is an increasing trend. With theimprovement of living standards, changes in eating habits and socialenvironment, the incidence of diabetes also increased year by year, and35%-75%of patients with diabetes have varying degrees of erectiledysfunction. Currently, the first-line drug for the treatment of erectiledysfunction phosphodiesterase-5inhibitors, but not for all ED patients arevalid, such as its efficacy in the treatment of diabetic ED patients less thanideal. In recent years, with the deepening of the stem cell research, stem celltransplantation to repair tissue damage, improve tissue remodeling to becomea reality. The purpose of this experiment is to To assess whether bone marrowderived mesenchymal stem cells(BM-MSC) have therapeutic effects ondiabetic erectile dysfunction.Methods: Male Sprague-Dawley rats were injected with streptozotocin toinduce DM. The diabetic rats with ED were selected by hypodermic injectionof apomorphine after12weeks of model setting.The model is made after therats were divided into three groups: normal control group, the diabetic EDuntreated group(negative control) and diabetic ED stem cells in the treatmentgroup.Whole bone marrow were isolated and cultured bone marrowmesenchymal stem cells. Then BM-MSC cultured third-generation DiI labeledstem cells, and injected into the rat corpus cavernosum. After injection,respectively, at3days,7days,2weeks,4weeks by ELISA Determination ofthe concentration of VEGF in the blood. ICP value of each group of rats wasmeasured after4weeks, and the determination of the content of the nNOSnerve fibers and smooth muscle cells in the rat corpuscavernosumimmunohistochemical method. Results: ICP value of stem cells in the treatment group compared with thenegative control group and diabetic ED group was significantly higher, but thetwo groups of ICP values were lower than the normal control group. Neuronalnitric oxide synthase(nNOS)-positive nerve fibers and smooth muscle cellswere fewer in DM-ED than in BM-MSC. However, the two groups of thenumber less than the normal control group. VEGF concentration in the treatedrats blood stem cells3days after injection, compared with the untreated groupwas significantly higher, and7days peaked.Conclusion: DM is associated with abnormalities in both the nerves andsmooth muscle. Treatment with BM-MSC ameliorates these adverse effectsand holds promise as a potential new therapy for ED. Through the study of thesubject, the following conclusions can be drawn:1, BM-MSC in the treatmentof diabetic ED can significantly improve their erectile function;2, BM-MSCin the treatment of diabetic ED can significantly increase the corpuscavernosumnNOS nerve fibers and corpus cavernosum smooth muscle content;3, It increases in the concentration of VEGF in the blood,7days to peak;4,BM-MSCs cultured third-generation, cell than pure and the quantity is moresuitable for use in experiments;5, the production of a diabetic rat model byintraperitoneal injection of streptozotocin dose65mg/kg when easier into themodel;6, there are many factors in the pathogenesis of diabetic erectiledysfunction, at least the presence of nerve and vascular factors;7, Currently,BM-MSC therapy mechanism is not yet clear, but the stem cells secretedfactors(such as VEGF) plays a certain role.